Related Experiment Video
Updated: May 2, 2026
05:52
Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
Published on: August 19, 2021
13.7K
Sentinel lymph node biopsy in melanoma: controversies and current guidelines
Alison B Durham1, Sandra L Wong
1Department of Dermatology, University of Michigan Medical School, Ann Arbor, MI, USA.
Future Oncology (London, England)
|February 25, 2014
Summary
Rising melanoma incidence necessitates accurate staging. Sentinel lymph node biopsy (SLNB) is crucial for staging localized melanoma, potentially offering survival benefits beyond initial diagnosis.
Area of Science:
- Oncology
- Surgical Pathology
Background:
- Melanoma incidence is increasing globally.
- Localized melanoma has a good prognosis, but advanced stages fare poorly.
- Accurate staging is vital for effective melanoma treatment.
Purpose of the Study:
- To review current data guiding sentinel lymph node biopsy (SLNB) patient selection in melanoma.
- To highlight controversial aspects of SLNB in melanoma management.
Main Methods:
- Review of current clinical data and guidelines.
- Analysis of evidence supporting SLNB for melanoma staging.
- Discussion of the benefits and controversies surrounding SLNB.
Main Results:
- Sentinel lymph node biopsy (SLNB) is supported by current data for staging appropriate melanoma patients.
- SLNB may provide benefits beyond initial staging.
- Specific areas regarding patient selection for SLNB remain controversial.
Conclusions:
- Sentinel lymph node biopsy (SLNB) is a key procedure for staging clinically localized melanoma.
- Further research is needed to confirm a survival advantage for SLNB.
- Current guidelines support SLNB for staging, despite ongoing controversies in patient selection.
